CRLF2, pairs with the IL-7Rα chain to form the functional TSLP receptor. TSLP signaling promotes dendritic cell maturation, Th2 cell differentiation, and eosinophil recruitment. Solrikitug's blockade of CRLF2 disrupts this cascade, reducing airway inflammation, IgE production, and tissue damage in TSLP-driven disorders, offering a targeted approach for patients with uncontrolled type 2 inflammation.